AI misses 14% of invasive breast cancers on mammography, with luminal cancers and dense tissue posing significant challenges.
Key Details
- 1Study analyzed 1,097 breast cancers from 1,082 women using Lunit Insight MMG AI between 2014–2020.
- 2AI missed 154 cancers (14%), often in younger women with smaller (<2 cm), lower-grade tumors and dense breasts.
- 3Missed cancers were more likely luminal subtype (false-negative rate 17.2%), compared to HER2-enriched (9%) and triple-negative (14.5%).
- 4Major reasons for AI misses included dense breast tissue (n=56), nonmammary zone location (n=22), architectural distortion (n=12), and amorphous calcifications (n=5).
- 561.7% of AI-missed cancers were deemed 'actionable' on further review by radiologists.
Why It Matters
Understanding which cancer features are often overlooked by AI tools enables radiologists to better interpret AI results, reducing missed diagnoses. These insights highlight the continued importance of human expertise in mammography, especially for high-risk groups like women with dense breast tissue.
Source
AuntMinnie
Related News
•AI in Healthcare
Landmark AI Mammography Trial and CMS Launches AI Prior Authorization Pilot
New large randomized trial to test AI in mammography screening, while CMS launches a multi-state pilot using AI for Medicare prior authorizations.
•AuntMinnie
AI for Breast Cancer Screening Not Cost-Effective, Study Finds
AI-assisted breast cancer screening showed minor clinical benefits over DBT alone but was not cost-effective at standard willingness-to-pay thresholds.
•Radiology Business
AI-Generated Reports Cut Radiology Reading Times and Gain Acceptance
AI-generated reporting significantly reduces radiologists' reading times and increases report acceptability over time.